We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-2.95%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$333M
Cap. Flow
-$249M
Cap. Flow %
-22.11%
Top 10 Hldgs %
64.02%
Holding
82
New
15
Increased
14
Reduced
31
Closed
17
Avg Time Held Equity + Options
1.7 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
1.8 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
1.3 years

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$16.3M
2
BRKR icon
Bruker
BRKR
+$13.9M
3
TFX icon
Teleflex
TFX
+$12.7M
4
PCVX icon
Vaxcyte
PCVX
+$12.7M
5
EW icon
Edwards Lifesciences
EW
+$11.9M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$79.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$64.4M
3
UTHR icon
United Therapeutics
UTHR
+$32.1M
4
TECH icon
Bio-Techne
TECH
+$26.7M
5
CYH icon
Community Health Systems
CYH
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Miscellaneous 13.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PCVX icon
26
Vaxcyte
PCVX
$10B
$10.4M 0.93%
+127,588
New +$12.7M
2024 Q4
0 quarters
TVTX icon
27
Travere Therapeutics
TVTX
$4.68B
$8.54M 0.76%
490,296
-379,617
-44% -$6.71M
2024 Q1
3 quarters
CYH icon
28
Community Health Systems
CYH
$406M
$8.45M 0.75%
2,827,000
-5,949,455
-68% -$25M
2020 Q4
16 quarters
GH icon
29
Guardant Health
GH
$21.3B
$8.43M 0.75%
+276,036
New +$7.77M
2024 Q4
0 quarters
RGEN icon
30
Repligen
RGEN
$11.1B
$7.78M 0.69%
54,066
-109,527
-67% -$15.7M
2021 Q1
15 quarters
IONS icon
31
Ionis Pharmaceuticals
IONS
$7.14B
$7.51M 0.67%
214,952
-256,403
-54% -$9.58M
2021 Q2
14 quarters
FTRE icon
32
Fortrea Holdings
FTRE
$2.14B
$7.49M 0.67%
401,733
-56,234
-12% -$1.1M
2024 Q3
1 quarter
NAMS icon
33
NewAmsterdam Pharma
NAMS
$2.37B
$7.08M 0.63%
275,362
-31,995
-10% -$680K
2023 Q1
7 quarters
AZN icon
34
AstraZeneca
AZN
$257B
$6.73M 0.6%
+51,331
New +$7.19M
2024 Q4
0 quarters
LQDA icon
35
Liquidia Corp
LQDA
$3.07B
$6.72M 0.6%
571,305
+433,356
+314% +$4.74M
2021 Q1
15 quarters
MEDP icon
36
Medpace
MEDP
$17.3B
$6.33M 0.56%
+19,049
New +$6.46M
2024 Q4
0 quarters
XENE icon
37
Xenon Pharmaceuticals
XENE
$3.24B
$6.1M 0.54%
+155,540
New +$6.43M
2024 Q4
0 quarters
MNKD icon
38
MannKind Corp
MNKD
$977M
$5.86M 0.52%
911,025
-1,081,479
-54% -$7.25M
2024 Q1
3 quarters
HUM icon
39
Humana
HUM
$49.6B
$5.75M 0.51%
22,682
-11,178
-33% -$3M
2022 Q2
10 quarters
HSIC icon
40
Henry Schein
HSIC
$9.63B
$5.56M 0.49%
+80,303
New +$5.77M
2024 Q4
0 quarters
DHR icon
41
Danaher
DHR
$161B
$5.1M 0.45%
22,209
-16,220
-42% -$3.99M
2018 Q3
25 quarters
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.15B
$4.54M 0.4%
343,400
-3,761,913
-92% -$64.4M
2022 Q2
10 quarters
PDCO icon
43
DELISTED
Patterson Companies, Inc.
PDCO
$4.51M 0.4%
+146,051
New +$3.39M
2024 Q4
0 quarters
GOSS icon
44
Gossamer Bio
GOSS
$53.6M
$4.5M 0.4%
62,231
– –
2021 Q3
13 quarters
EOLS icon
45
Evolus
EOLS
$469M
$4.23M 0.38%
383,045
-70,016
-15% -$985K
2024 Q2
2 quarters
ICLR icon
46
Icon
ICLR
$13.1B
$4.04M 0.36%
19,252
+5,584
+41% +$1.3M
2021 Q3
13 quarters
SUPN icon
47
Supernus Pharmaceuticals
SUPN
$2.21B
$3.82M 0.34%
+105,581
New +$3.72M
2024 Q4
0 quarters
AVTR icon
48
Avantor
AVTR
$11.1B
$3.55M 0.31%
168,369
– –
2023 Q3
5 quarters
PBYI icon
49
Puma Biotechnology
PBYI
$507M
$3.04M 0.27%
996,102
-297,155
-23% -$865K
2021 Q3
13 quarters
TSVT icon
50
DELISTED
2seventy bio
TSVT
$2.95M 0.26%
1,003,678
+5,599
+0.6% +$23K
2023 Q3
5 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Eversept Partners held 82 positions worth $1.13B, down 23% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners withdrew a net $249M in Q4 2024, closing 17 positions and reducing 31 holdings. Its most notable exit was Insmed, an estimated $79.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Bruker worth $13.8M.

  • Eversept Partners's largest Q4 2024 buy was Bruker: 234,934 shares worth $13.8M.
  • Eversept Partners added most to HCA Healthcare in Q4 2024, an estimated $16.3M increase.
  • Eversept Partners's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $64.4M.
  • Eversept Partners fully exited Insmed in Q4 2024, selling an estimated $79.5M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.13B portfolio in Q4 2024.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2024.
  • Eversept Partners's portfolio value fell 23% quarter-over-quarter to $1.13B.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.